Once-Daily Tiotropium Respimat Added-On to Inhaled Corticosteroids in a 1-Year Study in Adolescent Patients With Symptomatic Asthma Is Efficacious and Well Tolerated

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 699A
Author(s):  
Jonathan Bernstein ◽  
Attilio Boner ◽  
Eckard Hamelmann ◽  
Mandy Avis ◽  
John Downie ◽  
...  
Keyword(s):  
Inhaled Corticosteroids ◽  
Once Daily ◽  
Adolescent Patients ◽  
Symptomatic Asthma

Efficacy and Safety of Once-daily Tiotropium Respimat®Add-on Therapy over 1 Year in Adolescent Patients with Moderate Symptomatic Asthma

PEDIATRICS ◽  
2016 ◽  
Vol 137 (Supplement 3) ◽  
pp. 203A-203A
Author(s):  
Lyndon Mansfield ◽  
Petra Moroni-Zentgraf ◽  
Michael Engel ◽  
Mandy Avis ◽  
Reinhold Lühmann ◽  
...  
Keyword(s):  
Efficacy And Safety ◽  
Once Daily ◽  
Adolescent Patients ◽  
Symptomatic Asthma

Once-Daily Tiotropium Respimat Add-On to Medium-Dose ICS Is an Efficacious 24-Hour Bronchodilator in Adolescent Patients With Symptomatic Asthma

CHEST Journal ◽  
2014 ◽  
Vol 146 (4) ◽  
pp. 698A ◽  
Author(s):  
Christian Vogelberg ◽  
Michael Engel ◽  
Petra Moroni-Zentgraf ◽  
Migle Leonaviciute-Klimantaviciene ◽  
Ralf Sigmund ◽  
...  
Keyword(s):  
Once Daily ◽  
Adolescent Patients ◽  
Symptomatic Asthma ◽  
Medium Dose

Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids

2012 ◽  
Vol 109 (5) ◽  
pp. 353-358.e4 ◽  
Author(s):  
Eugene R. Bleecker ◽  
Eric D. Bateman ◽  
William W. Busse ◽  
Ashley Woodcock ◽  
Lucy Frith ◽  
...  
Keyword(s):  
Low Dose ◽  
Inhaled Corticosteroids ◽  
Fluticasone Furoate ◽  
Once Daily ◽  
Symptomatic Asthma

Once-Daily Tiotropium Is Well Tolerated as Add-On to Standard Treatment for Patients With Symptomatic Asthma Despite Receiving Inhaled Corticosteroids and Long-Acting β 2 -Agonists

CHEST Journal ◽  
2013 ◽  
Vol 144 (4) ◽  
pp. 89A ◽  
Author(s):  
Jonathan A Bernstein ◽  
Huib AM Kerstjens ◽  
Petra Moroni-Zentgraf ◽  
Michael Engel ◽  
Hendrik Schmidt ◽  
...  
Keyword(s):  
Standard Treatment ◽  
Inhaled Corticosteroids ◽  
Once Daily ◽  
Symptomatic Asthma ◽  
Long Acting

Once-Daily Tiotropium Reduces Risk of Exacerbations and Asthma Worsening in Patients With Symptomatic Asthma Despite Treatment With Inhaled Corticosteroids and Long-Acting β 2 -Agonists

CHEST Journal ◽  
2013 ◽  
Vol 144 (4) ◽  
pp. 90A ◽  
Author(s):  
Donald P Tashkin ◽  
Petra Moroni-Zentgraf ◽  
Michael Engel ◽  
Hendrik Schmidt ◽  
Huib AM Kerstjens
Keyword(s):  
Inhaled Corticosteroids ◽  
Once Daily ◽  
Symptomatic Asthma ◽  
Long Acting

scholarly journals A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma

2016 ◽  
Vol 49 (1) ◽  
pp. 1601100 ◽  
Author(s):  
Eckard Hamelmann ◽  
Jonathan A. Bernstein ◽  
Mark Vandewalker ◽  
Petra Moroni-Zentgraf ◽  
Daniela Verri ◽  
...  
Keyword(s):  
Asthma Control ◽  
Inhaled Corticosteroids ◽  
Controlled Trial ◽  
Forced Expiratory Volume ◽  
Phase Iii ◽  
Double Blind ◽  
Once Daily ◽  
Symptomatic Asthma ◽  
Baseline Response ◽  
Randomised Controlled

We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents with severe symptomatic asthma.In this double-blind, parallel-group trial (NCT01277523), 392 patients aged 12–17 years were randomised to receive once-daily tiotropium 5 µg or 2.5 µg, or placebo, as an add-on to ICS plus other controller therapies over 12 weeks. The primary and key secondary end-points were change from baseline (response) in peak forced expiratory volume in 1 s (FEV1) within 3 h post-dosing (FEV1(0–3h)) and trough FEV1, respectively, after 12 weeks of treatment.Tiotropium 5 µg provided numerical improvements in peak FEV1(0–3h) response, compared with placebo (90 mL; p=0.104), and significant improvements were observed with tiotropium 2.5 µg (111 mL; p=0.046). Numerical improvements in trough FEV1 response and asthma control were observed with both tiotropium doses, compared with placebo. The safety and tolerability of tiotropium were comparable with those of placebo.Once-daily tiotropium Respimat add-on to ICS plus one or more controller therapies in adolescents with severe symptomatic asthma was well tolerated. The primary end-point of efficacy was not met, although positive trends for improvements in lung function and asthma control were observed.

Sign in / Sign up

Export Citation Format

Share Document